絞り込み

16645

広告

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.

著者 Zoi I , Karamouzis MV , Xingi E , Sarantis P , Thomaidou D , Lembessis P , Theocharis S , Papavassiliou AG
Breast Cancer Res.2019 Dec 03 ; 21(1):132.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (9view , 0users)

Full Text Sources

Miscellaneous

ERBB-2 is overexpressed in about 20% of breast cancers (BCs), indicating poor prognosis. The receptor activator of nuclear factor-κB (RANK) pathway is implicated in ERBB-2 (+) BC. The purpose of this study was to elucidate the underlying molecular mechanism of this interaction and the beneficial impact of dual targeting of RANK and ERBB-2 pathways.
PMID: 31796128 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード